- Otsuka reports long-term kidney data key to Voyxact's bid for full approvalOtsuka on Thursday reported new long-term data that it hopes will convert an accelerated approval to a full green light in kidney disease. The company said the Phase 3 study showed Voyxact stabil…Endpoints · 22d ago↗ source
- IPF biotech Celea gets $180M to follow paths of PureTech's Karuna, SeaportWith major backing from new investors, Celea Therapeutics hopes to follow in the footsteps of its siblings Seaport Therapeutics and Karuna Therapeutics. Celea has corralled $180 million to see ifEndpoints · 22d ago↗ source
- Vertex's sickle cell therapy approved for kids; United Therapeutics buys startup🧬 Vertex’s sickle cell gene therapy approved for kids: Casgevy may now be used to treat either sickle cell disease with recurrent vaso-occlusive crises or transfusion-dependent β-thalassemia patie…